These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22926639)

  • 41. Novel agents in epithelial ovarian cancer.
    See HT; Kavanagh JJ
    Cancer Invest; 2004; 22 Suppl 2():29-44. PubMed ID: 15573743
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs.
    Moioli M; Barra F; Maramai M; Valenzano Menada M; Vellone VG; Costantini S; Ferrero S
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1025-1029. PubMed ID: 31726889
    [No Abstract]   [Full Text] [Related]  

  • 43. Setting the bar higher for ovarian cancer survival.
    Jenks S
    J Natl Cancer Inst; 2014 Feb; 106(2):dju037. PubMed ID: 24511114
    [No Abstract]   [Full Text] [Related]  

  • 44. Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells.
    Yang W; Kim D; Kim DK; Choi KU; Suh DS; Kim JH
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34064635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epigenetic therapy for ovarian cancer: promise and progress.
    Moufarrij S; Dandapani M; Arthofer E; Gomez S; Srivastava A; Lopez-Acevedo M; Villagra A; Chiappinelli KB
    Clin Epigenetics; 2019 Jan; 11(1):7. PubMed ID: 30646939
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An overview of early investigational therapies for chemoresistant ovarian cancer.
    Marchetti C; Ledermann JA; Benedetti Panici P
    Expert Opin Investig Drugs; 2015; 24(9):1163-83. PubMed ID: 26206420
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of targeted therapy in ovarian cancer.
    Banerjee S; Kaye S
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S116-30. PubMed ID: 21943965
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
    Teplinsky E; Muggia F
    Gynecol Oncol; 2014 Nov; 135(2):364-70. PubMed ID: 25220628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trial design for testing new therapies in ovarian cancer.
    Eisenhauer EA
    Int J Gynecol Cancer; 2005; 15 Suppl 3():258-65. PubMed ID: 16343242
    [No Abstract]   [Full Text] [Related]  

  • 50. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    Gralewska P; Gajek A; Marczak A; Rogalska A
    J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting the epigenome in ovarian cancer.
    Murphy SK
    Future Oncol; 2012 Feb; 8(2):151-64. PubMed ID: 22335580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The current status of PARP inhibitors in ovarian cancer.
    McLachlan J; George A; Banerjee S
    Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proteomics of ovarian cancer: functional insights and clinical applications.
    Elzek MA; Rodland KD
    Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.
    OʼSullivan Coyne G; Chen A; Kummar S
    Curr Opin Oncol; 2015 Nov; 27(6):475-81. PubMed ID: 26447876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Ovarian cancer-criteria of response and the timing of regimen change in chemotherapy for ovarian cancer].
    Takeuchi S; Takada A; Sugiyama T
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1471-6. PubMed ID: 23064058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting the tumour microenvironment in ovarian cancer.
    Hansen JM; Coleman RL; Sood AK
    Eur J Cancer; 2016 Mar; 56():131-143. PubMed ID: 26849037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.
    Bai H; Cao D; Yang J; Li M; Zhang Z; Shen K
    J Cell Mol Med; 2016 Apr; 20(4):581-93. PubMed ID: 26800494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aptamers as potential therapeutic agents for ovarian cancer.
    Henri JL; Macdonald J; Strom M; Duan W; Shigdar S
    Biochimie; 2018 Feb; 145():34-44. PubMed ID: 29224849
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Malignant ascites in ovarian cancer and the role of targeted therapeutics.
    Smolle E; Taucher V; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1553-61. PubMed ID: 24692682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.